#77 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Cannabinoid hyperemesis syndrome (CHS) is an increasingly recognized condition in adolescents that can present with severe, intractable nausea and vomiting, and clinicians need effective treatment options beyond standard antiemetics. This study demonstrates that aprepitant, an NK1 receptor antagonist, may provide relief for CHS patients who fail conventional treatments, offering clinicians a pharmacological tool to address this emerging cannabis-related complication. For patients, particularly teenagers, this finding provides an evidence-based treatment option that could reduce hospitalizations and improve quality of life while addressing the underlying cannabinoid use.
Cannabinoid hyperemesis syndrome (CHS), characterized by severe cyclic nausea and vomiting triggered by chronic cannabis use, is an increasingly recognized clinical problem in adolescent populations as cannabis use rates rise. This study demonstrates that aprepitant, an FDA-approved neurokinin-1 receptor antagonist commonly used for chemotherapy-induced nausea, effectively alleviates symptoms in teenage patients with CHS, offering a pharmacological alternative to the standard management approach of cannabis cessation alone. The mechanism likely involves aprepitant’s modulation of substance P signaling in the brain’s chemoreceptor trigger zone, which may counteract cannabis-related neurogenic inflammation. This finding is particularly relevant for clinicians treating adolescents who may be unwilling or unable to immediately discontinue cannabis use, as aprepitant provides symptomatic relief while addressing the underlying hyperemetic response. Understanding that CHS can present with severe dehydration and electrolyte abnormalities in younger patients warrants heightened clinical vigilance in this population. Clinicians should consider aprepitant as an adjunctive option when managing CHS in teenagers, particularly when cannabis cessation is not immediately achievable.
“We’re seeing preliminary signals that aprepitant, an NK1 receptor antagonist already proven for chemotherapy-induced nausea, may help manage cannabinoid hyperemesis syndrome in adolescents, but this is early work we need to see replicated in larger, controlled trials before making it standard practice for this population.”
🤢 While cannabinoid hyperemesis syndrome remains an uncommon but severe presentation in adolescent cannabis users, the potential utility of aprepitant—a neurokinin-1 receptor antagonist already established for chemotherapy-induced nausea—warrants clinical attention given the limited evidence base for treating this condition. The proposed mechanism involving substance P and the antiemetic pathway differs from cannabis’s direct cannabinoid receptor effects, suggesting a potentially rational pharmacologic approach, though the evidence from this work appears preliminary and should be interpreted cautiously in the context of the heterogeneous presentations of CHS and variable cannabis use patterns among teenagers. Critical confounders include the difficulty isolating cannabis as the sole etiology in adolescents who may use multiple substances, the role of behavioral factors and cessation, and whether aprepitant’s benefit reflects true disease modification or symptom management pending cannabis discontinuation. Clinicians encountering adolescents with rec
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
